Insulator dysfunction and oncogene activation in IDH mutant gliomas

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Gain-of-function mutations in isocitrate dehydrogenase (IDH) define key glioma subclasses.
• Mutant IDH produces 2-hydroxyglutarate, inhibiting TET hydroxylases involved in DNA demethylation.
• IDH mutant gliomas exhibit a CpG island methylator phenotype (G-CIMP), but its functional role is unclear.

Purpose of the Study:

• To investigate the functional consequences of altered DNA methylation in IDH mutant gliomas.
• To determine the role of CCCTC-binding factor (CTCF) in IDH-mutant gliomagenesis.
• To elucidate the mechanisms by which IDH mutations promote aberrant gene expression and glioma development.

Main Methods:

• Analysis of DNA methylation patterns at cohesin and CTCF-binding sites in human IDH mutant gliomas.
• Assessment of CTCF binding, DNA methylation, and gene expression in IDH mutant and wild-type gliomaspheres.
• Utilized CRISPR-Cas9 technology to disrupt CTCF motifs in IDH wild-type gliomaspheres.

Main Results:

• IDH mutant gliomas show hypermethylation at CTCF-binding sites, reducing CTCF binding and disrupting topological domain insulation.
• Loss of CTCF binding at domain boundaries allows aberrant enhancer interaction with the PDGFRA oncogene.
• Demethylating agents partially restored insulator function and downregulated PDGFRA in IDH mutant gliomaspheres.
• Disruption of CTCF motifs in IDH wild-type gliomaspheres upregulated PDGFRA and increased proliferation.

Conclusions:

• IDH mutations promote gliomagenesis by disrupting chromosomal topology via epigenetic alterations.
• Impaired CTCF insulator function leads to aberrant gene activation, specifically of the PDGFRA oncogene.
• Targeting epigenetic dysregulation offers a potential therapeutic strategy for IDH-mutant gliomas.